Edesa Biotech (EDSA) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Zhengye Biotechnology (ZYBT) over the past year, gaining 34.6% versus a loss of 62.7%. Zhengye Biotechnology is the larger company by market cap ($55.0 million vs $48.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | ZYBT |
|---|---|---|
| Share price | $3.56 | $1.16 |
| Market cap | $48.10M | $54.97M |
| 1-day change | -2.73% | +0.88% |
| YTD return | +157.75% | -0.01% |
| 1-year return | +34.56% | -62.67% |
| 5-year return | -93.31% | — |
| EPS (TTM) | $-1.72 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $8.01 |
| 52-week low | $0.72 | $0.616 |
| Distance from 52-week high | -82.48% | -85.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +358.71% | — |
| Average volume | 61.89K | 5.10M |
| Shares outstanding | 13.51M | 47.39M |
| Employees | 17 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed ZYBT by 97.2 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
EDSA vs ZYBT FAQ
Which is bigger, Edesa Biotech or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $54.97M compared with $48.10M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or ZYBT?
EDSA returned +34.56% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.